Vanessa A. Jacobsen, Pharm D
About Vanessa A. Jacobsen, Pharm D
Vanessa A. Jacobsen, Pharm D, serves as the Executive Director of Medical Science Liaisons at Nektar Therapeutics, bringing extensive experience in medical affairs and national accounts. She has held various significant roles at The Janssen Pharmaceutical Companies of Johnson & Johnson, contributing to the launch of numerous new molecular entities across multiple therapeutic areas.
Current Role at Nektar Therapeutics
Vanessa A. Jacobsen serves as the Executive Director of Medical Science Liaisons in Global Medical Affairs at Nektar Therapeutics. She has held this position since 2020, contributing to the company's strategic initiatives in medical affairs and enhancing the role of medical science liaisons within the organization.
Experience at The Janssen Pharmaceutical Companies
Jacobsen has extensive experience at The Janssen Pharmaceutical Companies of Johnson & Johnson, where she held multiple roles over several years. Her positions included Field Director for the Oncology Solid Tumor MSL Team, Scientific Director for National Accounts, and Strategic External Engagement Director for Janssen Oncology. She worked there from 2005 to 2020, accumulating a wealth of knowledge in health economics and clinical outcomes research.
Educational Background
Vanessa A. Jacobsen completed her Doctor of Pharmacy (PharmD) at the University of Illinois at Chicago. She also achieved a Pharmacy Practice Residency and a Fellowship in Solid Organ Transplantation from the same institution, which provided her with a strong foundation in clinical pharmacy and patient care.
National Account Experience
Jacobsen possesses extensive national account experience with major organizations, including Anthem, United Health Group, CVS Caremark, Humana, Veterans Administration, and Premier. This experience has equipped her with a deep understanding of the healthcare landscape and the ability to navigate complex organizational structures.
Achievements in Drug Launches
Throughout her career, Jacobsen has been involved in the launch of over 15 new molecular entities (NMEs) and more than 25 line-extensions across various therapeutic areas. These areas include Oncology, Immunology, Cardiovascular, Metabolics, Neuroscience, and Infectious Diseases, showcasing her expertise in drug development and market introduction.